These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 30175625

  • 1. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 2. Antibacterial R&D incentives.
    Laxminarayan R, Powers JH.
    Nat Rev Drug Discov; 2011 Sep 30; 10(10):727-8. PubMed ID: 21959280
    [No Abstract] [Full Text] [Related]

  • 3. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B, Sharma P, Rex JH.
    Nat Rev Drug Discov; 2012 Feb 01; 11(2):168. PubMed ID: 22293569
    [No Abstract] [Full Text] [Related]

  • 4. Antibiotic development - economic, regulatory and societal challenges.
    Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N.
    Nat Rev Microbiol; 2020 May 01; 18(5):267-274. PubMed ID: 31745330
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Fix the antibiotics pipeline.
    Cooper MA, Shlaes D.
    Nature; 2011 Apr 07; 472(7341):32. PubMed ID: 21475175
    [No Abstract] [Full Text] [Related]

  • 7. Drug development: Time for teamwork.
    May M.
    Nature; 2014 May 01; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antibiotic research and development: business as usual?
    Harbarth S, Theuretzbacher U, Hackett J, DRIVE-AB consortium.
    J Antimicrob Chemother; 2015 May 01; 70(6):1604-7. PubMed ID: 25673635
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE, Morel CM.
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec 01; 19(6):685-692. PubMed ID: 31847613
    [Abstract] [Full Text] [Related]

  • 12. The drug push.
    Servick K.
    Science; 2015 May 22; 348(6237):850-3. PubMed ID: 25999488
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. R&D efficiency of leading pharmaceutical companies - A 20-year analysis.
    Schuhmacher A, Wilisch L, Kuss M, Kandelbauer A, Hinder M, Gassmann O.
    Drug Discov Today; 2021 Aug 22; 26(8):1784-1789. PubMed ID: 34022459
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Discontinued drugs in 2010: oncology drugs.
    Williams R.
    Expert Opin Investig Drugs; 2011 Nov 22; 20(11):1479-96. PubMed ID: 21955127
    [Abstract] [Full Text] [Related]

  • 19. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
    Kesselheim AS, Outterson K.
    Health Aff (Millwood); 2010 Sep 22; 29(9):1689-96. PubMed ID: 20820028
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.